-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Eosinophilia: A Pragmatic Approach to Diagnosis and Treatment

Program: Education Program
Session: Cytosis: Too Much of a Good Thing
Saturday, December 5, 2015, 2:00 PM-3:30 PM
W224, Level 2 (Orange County Convention Center)
Sunday, December 6, 2015, 7:30 AM-9:00 AM
Valencia A (W415A), Level 4 (Orange County Convention Center)

Amy D Klion, MD

Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, Bethesda, MD

Disclosures: Off Label Use: No drugs, with the exception of imatinib, are FDA-approved for the treatment of hypereosinophilic syndromes. Consequently, all therapies to be discussed, including corticosteroids, hydroxyurea, interferon, mepolizumab, reslizumab, and benralizumab, are off-label. .

See more of: Cytosis: Too Much of a Good Thing
See more of: Education Program
Previous Presentation | Next Presentation >>